Erdafitinib-Induced Secondary Maculopathy.

ABSTRACT:

Purpose

This work presents a case of secondary maculopathy associated with the use of erdafitinib (Balversa) for the management of bladder urothelial carcinoma with bony metastasis.

Methods

A case report is presented.

Results

A 58-year-old Hispanic man presented with blurry vision 3 weeks after starting erdafitinib for the management of bony metastases associated with urothelial carcinoma. A comprehensive evaluation identified multiple areas of subretinal fluid induced by erdafitinib. Throughout treatment, the ocular condition progressed, causing worsening of vision; this led to discontinuation of the drug. Discontinuation was associated with visual and anatomic function improvement.

Conclusions

Fibroblast growth factor receptor (FGFR) plays a major role in mai

SUBMITTER: Becker B 

PROVIDER: S-EPMC9976033 | biostudies-literature | 2022 Jul-Aug

REPOSITORIES: biostudies-literature